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Abstract. Recent significant advances in understanding
the biology of gastrointestinal stromal tumours (GIST)
have led to the introduction of a new targeted therapy
(imatinib mesylate, Glivec). Hopes of a new era of a spe-
cific cancer therapy, however, have been tempered by the
recognition that a significant proportion of patients who
initially respond to the drug eventually become resistant
to it. Given the successful development of peptide recep-
tor scintigraphy and radiotherapy for neuroendocrine tu-
mours, we postulated that a similar approach could offer
a valid alternative in the diagnosis and therapy of GIST.
Using in vitro receptor autoradiography to measure pep-
tide receptors, we found that 16/19 GIST expressed
bombesin subtype 2 receptors, 16/19 expressed vasoac-
tive intestinal peptide subtype 2 receptors (VPAC2) and
12/19 expressed cholecystokinin subtype 2 receptors, in
most cases in extremely high densities. All GIST metas-
tases were shown to express two or more of these pep-
tide receptors in very high density. Receptors were also
expressed in non-responders to Glivec or after chemo-
embolisation. Conversely, somatostatin subtype 2, chole-
cystokinin subtype 1, bombesin subtype 1 and 3, and
neuropeptide Y subtype Y1 and Y2 receptors were not or
only rarely expressed. These data represent a strong mo-
lecular basis for the use of radiolabelled bombesin, vaso-
active intestinal peptide and/or cholecystokinin ana-
logues as targeting agents to localise GIST tumours in
patients by in vivo scintigraphy and/or to perform target-
ed radiotherapy to destroy GIST primaries, metastases
and recurrences, including those resistant to Glivec.
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Introduction
Gastrointestinal stromal tumours (GIST) have gained in-
creasing interest in the past few years. First, the intersti-
tial cell of Cajal, an intestinal pacemaker cell, has been
suggested as the cell of origin of these tumours [1]. Sec-
ond, the recent recognition that most GIST have a gain-
of-function mutation in KIT proto-oncogene, resulting in
ligand-independent activation of the KIT receptor tyro-
sine kinase, sheds more light on their pathogenesis [2,
3]. Finally, a small molecule (STI 571, imatinib mesy-
late, Glivec) used for the treatment of chronic myeloid
leukaemia proved to be therapeutically effective in meta-
static GIST [4, 5] through selective inhibition of the en-
zymatic activity of the KIT tyrosine kinase pathway.
This latter major clinical advance, however, has been
hampered by the recognition that not all patients respond
adequately to Glivec, and that many of those who initial-
ly respond may become resistant to the treatment after
some time [6, 7, 8, 9]. Hence, the identification of alter-
native therapy modalities for GIST will represent a ma-
jor challenge for future clinical investigations. In this
context, it will also be very important to develop diag-
nostic tools able to detect small metastases and local re-
currences of GIST, thereby allowing treatment of the dis-
ease at an early stage.
In recent years, it has been shown that some human
cancers can overexpress specific peptide receptors and
that these can be targeted for either diagnostic or radio-
therapeutic purposes [10]. The best evidence has been
provided for somatostatin receptors expressed in neuro-
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endocrine tumours, which can currently be targeted with
111In-DTPA-octreotide for their in vivo localisation or
with 90Y-DOTATOC for targeted radiotherapy [11]. In-
deed, somatostatin receptor scintigraphy was shown to
be the diagnostic tool of first choice for a subgroup of
gut neuroendocrine tumours, as it was superior to all oth-
er conventional imaging methods [12], and radiotherapy
with 90Y-DOTATOC appears extremely promising in tu-
mours expressing somatostatin receptors, with more than
25% remissions and about 60% disease stabilisation [13,
14, 15, 16]. More recently, other peptide receptors have
emerged as being overexpressed in selected tumours [10]
and appear to have a strong in vivo targeting potential.
These are bombesin receptors of the BB2 subtype, better
known as gastrin-releasing peptide (GRP) receptors,
which are overexpressed in prostate and breast cancers
[10] and can be visualised in vivo in these tumours [17,
18]. Also cholecystokinin 2 (CCK2) receptors expressed
in medullary thyroid carcinomas (MTC) [10] can be se-
lectively targeted in vivo [19, 20].
Peptide receptors can also be expressed in normal tis-
sues. Of particular interest in relation to GIST is the fact
that somatostatin receptors, vasoactive intestinal peptide
(VIP) receptors, GRP receptors and substance P recep-
tors of the NK1 subtype were found to be expressed in
the putative precursor cell of GIST, namely the Cajal
cells of the gastrointestinal tract in animals as well as in
humans [21, 22]. In the present study we therefore inves-
tigated a number of peptide receptors, including the four
mentioned above, for their expression in GIST using in
vitro receptor autoradiography.
Materials and methods
The peptide receptors investigated in this study include bombesin
receptors [with their three subtypes, namely BB1 (NMB recep-
tors), BB2 (GRP receptors) and BB3], VIP receptors (VPAC1 and
VPAC2 subtypes), CCK1 and CCK2 receptors, somatostatin recep-
tors (sst2 receptors), substance P receptors (NK1 receptor subtype)
and neuropeptide Y (NPY) receptors (Y1 and Y2 subtypes). The
methodology used is in vitro receptor autoradiography identifying
the respective receptor proteins morphologically as specific bind-
ing sites. The methods used for the identification of the various re-
ceptors and their subtypes were reported in detail previously [23,
24, 25, 26, 27, 28]. Subtype-selective VIP receptor autoradiogra-
phy was performed using 125I-VIP (2,000 Ci/mmol, Anawa, 
Wangen, Switzerland) as radioligand with the VPAC1-selective
[K15, R16, L27]-VIP(1-7)GRP(8-27) and VPAC2-selective Ro25-
1553 [25]. Subtype-selective CCK receptor autoradiography was
performed using 125I-[D-Tyr-Gly, Nle28,31]-CCK26-33 (125I-CCK;
2,000 Ci/mmol, Anawa, Wangen, Switzerland) as radioligand, dis-
placed with CCK-8 or gastrin to discriminate between CCK1 and
CCK2 receptors [24]. Subtype-selective bombesin receptor auto-
radiography was performed using 125I-[D-Tyr6, β-Ala11, Phe13,
Nle14]-bombesin(6-14) (2,000 Ci/mmol, Anawa, Wangen, Switzer-
land) as radioligand, with unlabelled GRP, NMB and [D-Tyr6, 
β-Ala11, Phe13, Nle14]-bombesin(6-14) to discriminate between
GRP, NMB and BB3 receptors [27]. sst2 receptors were detected
with 125I-[Tyr3]-octreotide (2,000 Ci/mmol, Anawa, Wangen,
Switzerland) displaced with the sst2-selective ligand L-779-976
[28]. NK1 receptors were identified with 125I-Bolton-Hunter-SP
(2,000 Ci/mmol, Anawa, Wangen, Switzerland) as radioligand and
displaced with the NK1-selective agonist [Sar9, Met(O2)11]-SP
[23]. NPY receptors were detected with 125I-PYY (2,000 Ci/mmol,
Anawa, Wangen, Switzerland), using [Leu31, Pro34]-NPY as dis-
placer for Y1 receptors and PYY(3-36) as displacer for Y2 recep-
804
European Journal of Nuclear Medicine and Molecular Imaging Vol. 31, No. 6, June 2004
Table 1. Clinicopathologic data on 15 gastrointestinal stromal tumour primaries
Site Case Sex Age Tumour Mitotic Tumour Tumour grade: 
(yrs) size (cm) indexa necrosis NIH Consensus 
Conferenceb
a) Stomach 1 M 67 6 5 No Intermediate risk
2 F 48 7 6 Yes High risk
3 F 71 5 16 No High risk
4 M 42 8.5 2 No Intermediate risk
5 M 59 9 3 No Intermediate risk
6 M 69 4 1 No Very low risk
7 F 54 0.9 1 No Very low risk
8c F 49 20 54 Yes High risk
b) Small intestine 9 M 71 3 1 Yes Low risk
10 F 78 5 1 Yes Low risk
11c F 49 4 3 No Low risk
c) Mesentery/epiploon 12 M 69 12 21 No High risk
13 M 41 20 76 Yes High risk
14c F 67 21 2 No High risk
15c M 82 23 33 Yes High risk
a Number of mitoses/50 hpf (one high-power field: 0.174 mm2)
b Reference no. [7]
c Metastases at diagnosis
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tors [26]. In all experiments, the autoradiograms were quantified
using a computer-assisted image processing system, as described
previously [25, 26]. Radiolabelled tissue sections were exposed to
3H-Hyperfilms together with standards (Autoradiographic [125]mi-
croscales, Amersham) that contained known amounts of isotope,
cross-calibrated to tissue-equivalent ligand concentration. The im-
age analyser was calibrated to the standards; it performed interpo-
lation to read values that lay between those of the film standards.
A tumour was considered as receptor-positive when the optical
density measured over a tissue area in the total binding section
was at least twice that of the non-specific binding section. In the
present study, 19 frozen GIST samples were analysed (Tables 1,
2). The clinical data of the patients and the tumour characteristics
are listed in Table 1.
Results
All GIST tested in this study expressed peptide recep-
tors. Three of these peptide receptors, namely GRP
(BB2) receptors, VPAC2 receptors and CCK2 receptors,
were found with a very high incidence in these tumours
(Table 2). GRP receptors were found in 16/19 cases,
VPAC2 receptors were expressed in 16/19 tested cases
and CCK2 receptors were found in 12/19 cases, whereas
CCK1 receptors were present in only 3/19 cases. The ex-
traordinarily high density of all three receptors was re-
markable, with densities above 2,000 dpm/mg tissue be-
ing observed for GRP receptors in 10/19 tumours, for
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Fig. 1A–E. Characterisation of GRP receptors (BB2) in GIST.
A Haematoxylin-eosin stained section. Bar=1 mm. B Autoradio-
gram showing total binding of 125I-[D-Tyr6, β-Ala11, Phe13, Nle14]-
BN(6-14). C Autoradiogram showing non-specific binding in the
presence of 50 nM of unlabelled [D-Tyr6, β-Ala11, Phe13, Nle14]-
bombesin(6-14), as universal ligand. D Autoradiogram showing
125I-[D-Tyr6, β-Ala11, Phe13, Nle14]-BN(6-14) binding in the pres-
ence of 50 nM GRP. Full displacement is observed. E Autoradio-
gram showing 125I-[D-Tyr6, β-Ala11, Phe13, Nle14]-BN(6-14) bind-
ing in the presence of 50 nM NMB. Only weak displacement is
seen. Bottom part: Complete displacement curves in a GRP recep-
tor-expressing GIST. 125I-[D-Tyr6, β-Ala11, Phe13, Nle14]-BN(6-14)
is displaced by nanomolar concentrations of the unlabelled ana-
logue (●). Moreover, GRP (■) displaces the radioligand with high
affinity while NMB (▲) is much less active
Fig. 2A–F. Characterisation of VPAC2 receptors in GIST. Recep-
tor autoradiography showing a tumour (A haematoxylin-eosin
stained section, bar=1 mm) expressing VPAC2, measured either
with the VPAC2-selective radioligand 125I-Ro25-1553 [B total
binding; C non-specific binding (in the presence of 20 nM unla-
belled Ro25-1553)] or with the universal radioligand 125I-VIP 
(D total binding) displaced by 20 nM of Ro25-1553 (E) but not by
20 nM of the VPAC1-selective KRL-VIP/GRF (F). The two
graphs on the right show complete displacement curves either
with 125I-VIP as universal ligand (upper graph) displaced with
nanomolar concentrations of VIP (●) and Ro25-1553 (■) but not
KRL-VIP/GRF (▲), or with 125I- Ro25-1553 (lower graph) dis-
placed by Ro25-1553 (●) but not by KRL-VIP/GRF (▲)
807
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VPAC2 receptors in 9/19 tumours and for CCK2 recep-
tors in 9/19 tumours. In 16/19 tested GIST (84%), at
least one of these receptors was expressed with a very
high density. In many cases, the measured densities of
GRP, VPAC2 and/or CCK2 receptors reached levels high-
er than those usually found for the somatostatin recep-
tors in neuroendocrine gastroenteropancreatic tumours
[28]. Conversely, sst2 receptors, NK1 receptors, NMB
(BB1), BB3 and NPY receptors were found only rarely in
GIST, and, if present, usually in low to moderate density.
Compared with VPAC2, VPAC1 was rarely expressed,
and then only in low amounts. Furthermore, as reported
previously for other tumour types, vessels expressing
one or several peptide receptors, in particular NK1 or/and
NPY receptors, were frequently found in GIST. Fig-
ures 1, 2 and 3 show examples of tumours expressing
some of the most frequently found peptide receptors in
GIST, namely GRP, VPAC2 and CCK receptors. Figure 1
shows an example of a tumour expressing GRP receptors
(BB2). Figure 2 is an example of a tumour expressing a
high density of VPAC2 receptors. Figure 3 illustrates two
tumours having CCK receptors, one with CCK2, the oth-
er with CCK1 expression. In all examples, the pharmaco-
logical characteristics of the various receptors are also
presented in competition experiments. Figure 4 shows a
typical example of a GIST expressing concomitantly the
three receptors, GRP, VPAC2 and CCK2.
No correlations were found between receptor status
and any of the listed tumour characteristics, such as tu-
mour size, mitotic index or presence of tumour necrosis
(Tables 1, 2). There was no correlation between the re-
ceptor expression and the tumour localisation. However,
it should be mentioned that peptide receptors could be
identified in primary GIST in all locations, namely stom-
ach, small intestine and mesentery. It is, moreover, im-
portant to note that all GIST metastases expressed con-
comitantly at least two of the peptide receptors in very
high amounts. Finally, it should be stressed that the two
patients with a terminal condition that had been treated
prior to sampling (case 19 with Glivec, case 17 with 
chemo-embolisation) both retained a very high density
of several peptide receptors (Table 2).
Fig. 3A–H. Characterisation of CCK receptors in GIST. Upper
part: Receptor autoradiography of a CCK2 receptor-expressing
(A–D) and a CCK1 receptor-expressing (E–H) GIST. A, E Haema-
toxylin-eosin stained sections. Bars =1 mm. B, F Autoradiograms
showing total binding of 125I-CCK. C, G Autoradiograms showing
binding of 125I-CCK in the presence of 50 nM CCK. Full displace-
ment is seen in both cases. D, H Autoradiograms showing binding
of 125I-CCK in the presence of 50 nM gastrin. Displacement is
seen in D, but not in H, indicating CCK2 receptors in the upper
case and CCK1 in the lower case. Bottom part: Complete displace-
ment curves in a CCK2-expressing (left) and a CCK1-expressing
(right) GIST. In both cases, 125I-CCK was displaced by nanomolar
concentrations of CCK (●), whereas it was displaced by gastrin
(■) only in the left case
Fig. 4A–D. GIST (A haematoxylin-eosin stained section, bar=
1 mm) expressing concomitantly a high density of GRP receptors
(B autoradiogram showing total binding of 125I-[D-Tyr6, β-Ala11,
Phe13, Nle14]-bombesin(6-14)), VPAC2 receptors (C autoradio-
gram showing total binding of 125I-Ro25-1553) and CCK2 (D auto-
radiogram showing total binding of 125I-CCK). Full displacement
was seen with the respective subtype-selective analogues (data not
shown)
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Discussion
We report for the first time that GIST express high levels
of peptide receptors. These results may have an impor-
tant and immediate clinical impact. It should indeed be
possible to take advantage of the expression of these re-
ceptors to target GIST in vivo. Two different strategies
should be considered: first, the development of in vivo
receptor targeting of GIST for diagnostic purposes,
namely for the precise localisation and the early detec-
tion of GIST recurrences and metastases, which still re-
present a difficult clinical problem, especially after anti-
tyrosine kinase receptor therapy. Second, the develop-
ment of peptide receptor radiotherapy, either as an alter-
native to Glivec or as an adjuvant treatment, for cases
not responding or developing resistance to this drug.
Peptide receptor targeting of GIST for diagnostic pur-
poses could be successful in the relatively near future
since the basic methods have already been developed
and are available for two of the three peptide receptors
most often expressed in GIST. There is indeed good evi-
dence that GRP receptor-positive tumours can be local-
ised in vivo with radiolabelled bombesin analogues. Van
de Wiele et al. [17] were the first to report the visualisa-
tion of breast cancer; Scopinaro et al. [18] detected small
prostate cancer metastases with this method. Moreover,
CCK2 receptor-positive medullary thyroid carcinomas
(MTC) were successfully visualised with radiolabelled
gastrin or CCK analogues [19, 20]. The fact that GIST
express a density of CCK2 receptors much higher than
MTC, and a density of GRP receptors equal to or higher
than prostate and breast cancers, is a strong argument for
predicting successful visualisation of the smallest GIST
recurrences and metastases. Finally, methods for peptide
receptor radiotherapy have been developed that could be
applied to GIST. The best evidence has been provided by
the somatostatin receptor radiotherapy of neuroendocrine
tumours using radiolabelled octreotide derivatives; stud-
ies from various centres agree on a 25% remission rate
and a 60% stabilisation rate for somatostatin receptor-ex-
pressing neuroendocrine tumours using current protocols
[11, 14, 15, 16]. Moreover, in a small series of MTC pa-
tients, CCK2 receptor radiotherapy was also found to be
successful [29]. Although there is as yet no in vivo evi-
dence of successful VPAC2 targeting of human cancers,
specific VPAC2 analogues are available [30] which
should be developed as radioligands in order to take ad-
vantage of the very large number of VPAC2 in GIST.
Such VPAC2 receptor scintigraphy may, compared with
VIP receptor scintigraphy using 125I-VIP, be character-
ised by a much lower background of normal organs,
most frequently expressing VPAC1 receptors [10]. Ulti-
mately, if successful at a single level, one may try multi-
receptor targeting [10, 28] as a potentially more power-
ful strategy, including CCK2 receptor targeting in combi-
nation with GRP receptor targeting, and, once developed
for clinical use, with VPAC2 targeting.
With respect to the utilisation of the radiolabelled com-
pounds for diagnosis and therapy, an appropriate assess-
ment of the tumour to background ratio for the respective
receptors should be helpful. Such an assessment is, how-
ever, difficult in the gastrointestinal tract, since the back-
ground consists, in this complex organ, of several different
kinds of normal tissue (mucosa, muscles, nerves, immune
cells) with a distinct peptide receptor expression that may
also differ from one gut area to the other. Based on in vitro
data, the following can be stated: VPAC2 are primarily
distributed in the gut smooth muscles and vessels [21], but
not in the mucosa, which expresses VPAC1 [25]. CCK2 re-
ceptors are located in the smooth muscles and mucosa,
very predominantly in the stomach [21, 31]. GRP recep-
tors are located in the gut smooth muscles and nerves, but
not in the mucosa [21]. Although the receptor density
reaches significant levels in selected normal human tis-
sues (e.g. CCK2 in stomach), GIST tumours appear in
general to express a higher density of the respective recep-
tors. Furthermore, according to recent in vivo targeting
studies in humans, the presence of peptide receptors in the
normal gastrointestinal tract does not seem to affect sig-
nificantly the scintigraphic evaluation, an exception being
the CCK2 receptors in the stomach: With 123I-VIP scintig-
raphy (identifying VPAC1 and VPAC2), no clinically rele-
vant uptake of the tracer was obtained in the normal intes-
tinal mucosa [32], while using CCK2 receptor scintigra-
phy, strong uptake was detected in the stomach but not in
other parts of the gastrointestinal tract [33]. GRP receptor
scintigraphy with 99mTc-RP527 did not identify specific
uptake in the intestines, although enterohepatic clearance
of this tracer affected the interpretation of the scans at this
level [17, 34].
The fact that the cells of origin of GIST, the Cajal
cells [1], express several of these receptors in physiolog-
ical conditions is a possible explanation for the expres-
sion of these receptors in GIST. It remains unclear, how-
ever, why the GRP receptors, the VPAC2 receptors and
the CCK2 receptors are expressed in such a high inci-
dence and amount, whereas other receptors, also ex-
pressed in Cajal cells, such as the sst2 and NK1 receptors,
are only occasionally found in these tumours.
The very strong expression of three peptide receptors
in GIST also has potential biological implications. First,
GRP, VPAC2 and CCK2 receptors can be added to the
number of known biological markers characterising this
type of tumour. Second, knowing the strong growth-
stimulating properties of GRP, VIP and CCK [35, 36], it
is possible that all three peptides influence GIST growth
through their respective receptors. Thus, in addition to
activating mutations in the KIT receptor tyrosine kinase,
and to the recently characterised activating mutations in
the platelet-derived growth factor receptor [37], overex-
pression of peptide receptors may also have a significant
pathogenetic role in the progression of GIST.
In conclusion, our in vitro study shows that most
GIST express GRP, VPAC2 and/or CCK2 receptors. Al-
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though it is clear that successful in vivo application of
the present data will also depend on a variety of addi-
tional criteria [38, 39], the present receptor data predict
that radiolabelled bombesin, vasoactive intestinal pep-
tide and/or cholecystokinin analogues could be used as
targeting agents to localise GIST in patients by scintigra-
phy. They also suggest that targeted radiotherapy with
these radiolabelled peptides may offer an effective alter-
native to GIST treatment.
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